Trial Profile

Nivolumab, Ipilimumab and Radiation in Combination With Influenza Vaccine in Patients With Pancreatic Cancer (INFLUENCE)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 31 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Influenza virus vaccine (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms INFLUENCE

Most Recent Events

24 May 2024 Status changed from active, no longer recruiting to discontinued because the predictive probability was below 10% for the prespecified endpoint, based on the precpecified interim analysis.
26 Feb 2024 Planned End Date changed from 19 Oct 2023 to 19 Apr 2024.
15 Nov 2023 This trial has been discontinued, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com